Buy Sarepta (SRPT) Into Kyndrisa Briefing Documents and Panel Outcome - Oppenheimer

Concerns on Drisapersen Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company

Needham & Company analyst Chad Messer said FDA concerns on BioMarin's drisapersen should be a positive for Sarepta Therapeutic (NASDAQ: SRPT) Eteplirse. The firm reiterated a Buy rating and price target of $55.

Messer commented, "The FDA released briefing documents for BioMarin's drisapersen this... More

Sarepta Therapeutics (SRPT) Surges 25% Following BioMarin (BMRN) Briefing Docs

Sarepta Therapeutics (NASDAQ: SRPT) is trading up 25% following BioMarin Pharma's (NASDAQ: BMRN) FDA briefing docs on Drisapersen for treatment of DMD. Meanwhile, BMRN is down 7%.

Baird Expects FDA Rejection for Drisapersen and Eteplirsen (BMRN) (SRPT)

Baird analyst, Brian Skorney, increasing belief is that the FDA is more likely to reject the NDA's for drisapersen and eteplirsen. He thinks the risk-reward is mildly skewed to the upside for BioMarin Pharma (NASDAQ: BMRN) (20% up/10% down) and massively so for Sarepta Therapeutics (NASDAQ: SRPT) (250%... More

Jefferies Survey Suggests Positive Expectations for BioMarin (BMRN) Ahead of Data on 11/24

In a turn of events, Jefferies analyst, Gena Wang, surveyed 58 investors to find out expectations for upcoming therapy results and found the buy-sides expectations of 62/28/10% probability for positive/mixed/negative outcomes for BioMarin Pharma's (NASDAQ: BMRN) Kyndrisa (drisapersen). The results are expected... More

Sarepta Therapeutics (SRPT) Issues Publication of Positive Eteplirsen Phase 2b Long-Term Data in DMD

Sarepta Therapeutics (Nasdaq: SRPT) announced that the Annals of Neurology published online [link to final article] positive efficacy and safety results from a Phase IIb long-term open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study found that at three years of treatment, patients experienced a slower rate of disease progression when compared to untreated matched historical controls and the investigational drug continued to be well-tolerated.

This analysis used historical data from the Italian Telethon Network and the Leuven Neuromuscular Reference Group for comparative... More